Rafiq Mohamed, Azeemuddin Mohammed
Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore-562123 Karnataka.
Oman Med J. 2012 Nov;27(6):e010. doi: 10.5001/omj.2012.127.
The present study was conducted to evaluate the efficacy of Abana (a poly-ingredient formulation with natural constituents) on platelet aggregation and occlusion-induced deep venous thrombosis in rats.
Anti-platelet property of Abana was evaluated using ADP (Adenosin 5-diphosphate) and adrenaline-induced platelet aggregation models, and anti-thrombotic activity was evaluated against occlusion-induced deep venous thrombosis model in wistar rats.
Under the , Abana® (250, 500 and 1000 µg/ml) alleviated ADP and adrenaline-induced platelet aggregation in a dose-dependent manner. Abana® (1000 µg/ml) inhibited ADP and adrenaline-induced platelet aggregation by as much as 50.69% and 64.83% respectively. Furthermore, 6 days pre-treatment with Abana® (250 and 500 mg/kg, p.o.) in an study showed significant and dose-dependent protection against occlusion-induced deep venous thrombosis in rats.
These findings suggest that Abana, a polyherbal formulation possesses anti-platelet and anti-thrombotic activities in the experimental models of platelet aggregation and deep venous thrombosis in rats.
本研究旨在评估阿巴纳（一种含有天然成分的多成分制剂）对大鼠血小板聚集和闭塞诱导的深静脉血栓形成的疗效。
使用二磷酸腺苷（ADP）和肾上腺素诱导的血小板聚集模型评估阿巴纳的抗血小板特性，并针对Wistar大鼠的闭塞诱导的深静脉血栓形成模型评估其抗血栓活性。
在该条件下，阿巴纳®（250、500和1000μg/ml）以剂量依赖性方式减轻ADP和肾上腺素诱导的血小板聚集。阿巴纳®（1000μg/ml）分别抑制ADP和肾上腺素诱导的血小板聚集达50.69%和64.83%。此外，在一项研究中，用阿巴纳®（250和500mg/kg，口服）预处理6天显示出对大鼠闭塞诱导的深静脉血栓形成具有显著的剂量依赖性保护作用。
这些发现表明，阿巴纳这种多草药制剂在大鼠血小板聚集和深静脉血栓形成的实验模型中具有抗血小板和抗血栓活性。
